| Literature DB >> 35740773 |
Aleksandra Pietraś1, Grażyna Mielnik-Niedzielska1.
Abstract
Rhinosinusitis is an essential medical problem in pediatric populations. Due to a lack of studies considering allergy impact on pediatric rhinosinusitis, it seems legitimate to investigate this subject. The aim of this paper was to assess the influence of inhalant allergy on acute rhinosinusitis in children. The study involved 100 pediatric patients aged between 3 and 17 years who were admitted to the Chair and Department of Pediatric Otolaryngology, Phoniatrics and Audiology of the Medical University of Lublin due to acute rhinosinusitis. The control group consisted of 50 children without allergy, and the study group consisted of 50 children suffering from inhalant allergy. The methodology employed in this study involved medical history and laryngological examination, as well as laboratory and radiological testing. Dust mite allergy was the most common allergy among patients in the study group. Patients with allergies presented at the hospital later than patients without allergy, and their hospitalization lasted longer due to more severe sinus disease, higher inflammatory parameters, multiple sinus involvement, more frequent fever or rhinosinusitis complications, especially orbital occurrence. Most children in the control group required only pharmacological treatment. Inhalant allergy, especially dust mite allergy, contributes to more severe acute rhinosinusitis in children.Entities:
Keywords: acute rhinosinusitis; inhalant allergy; pediatric population
Year: 2022 PMID: 35740773 PMCID: PMC9222100 DOI: 10.3390/children9060836
Source DB: PubMed Journal: Children (Basel) ISSN: 2227-9067
Figure 1Severity of rhinosinusitis on the visual analog scale.
Figure 2Duration of hospitalization (in days).
Sinus involvement (apart from maxillary sinuses).
| Paranasal Sinuses | Study Group | Control Group | Statistical Analysis |
|---|---|---|---|
| Ethmoid | 26 (52%) | 15 (30%) | |
| Frontal | 20 (40%) | 13 (26%) | |
| Sphenoid | 16 (32%) | 7 (14%) |
Figure 3CRP values in the control and study groups.
Significant research outcomes.
| Studied Factor | Control Group | Study Group | |
|---|---|---|---|
| VAS score | 3–9 | 3–9 | 0.021 |
| 5.86 ± 1.47 | 5.16 ± 1.50 | ||
| Duration of hospitalization | 3–16 days | 3–16 days | 0.02 |
| 7 ± 3 days | 9 ± 3 days | ||
| C-reactive protein | 0.03–19.31 mg/dL | 0.03–26.25 mg/dL | 0.01 |
| mean: 2.93 mg/dL | mean: 4.66 mg/dL |